All stories tagged :

Sample Category Title

Sample Category Description. ( Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. )

Cure Hydration Launches in Ulta Beauty Stores, Expanding Access to Ingestible...

admin

Tháng 10 15

Pr Newswire

Hinge Bio Announces FDA Clearance of Investigational New Drug Application for...

admin

2 ngày ago

Pr Newswire

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically...

admin

2 ngày ago

Pr Newswire

Bybit Ties Welcome Gifts Program to MNT & BNB Rallies with...

admin

2 ngày ago

Pr Newswire

Chiron Medical Launches “Early Check, Early Hope” Campaign, Embracing Pink for...

admin

2 ngày ago

Pr Newswire

Markel International appoints Tom Hillier as CUO and announces new international...

admin

2 ngày ago

Pr Newswire

A Complete Guide to the Cambridge English Certificate: Key Information

admin

2 ngày ago

Pr Newswire

Daqo New Energy to Announce Unaudited Results for the Third Quarter...

admin

2 ngày ago

Pr Newswire

bioLytical’s iStatis Syphilis Antibody Test Now Included in the Australian Register...

admin

3 ngày ago

Pr Newswire

AdvanCell to present promising clinical trial results of ADVC001, a novel...

admin

3 ngày ago

Pr Newswire

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with...

admin

3 ngày ago

1 2 3 4 5 6 7 8 9 … 1.072 1.073 1.074 Page 6 of 1.074

Featured

Pr Newswire

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of...

admin

3 giờ ago

Pr Newswire

Extendicare Announces October 2025 Dividend of C$0.042 per Share

admin

3 giờ ago

Pr Newswire

First Key Update of the International AI Safety Report released

admin

3 giờ ago

Pr Newswire

ZETA NETWORK GROUP (NASDAQ: ZNB) STRENGTHENS BALANCE SHEET WITH USD 231...

admin

3 giờ ago

admin

3 giờ ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of...

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from GSK, combined with cash in hand and removal of future MARIO expenditures, extends the...